ARS Pharma up after Japan's approval for allergic reaction nasal spray
Drug developer ARS Pharmaceuticals' shares SPRY.O rise 7.7% to $10.69 premarket
Company says Japan's health regulator has approved its nasal spray, neffy, in 1 mg and 2 mg doses, for emergency treatment of allergic reactions in adults and children weighing over 15 kg
In 2020, ARS Pharma signed an exclusive licensing deal with Japan's Alfresa Holdings 2784.T, granting the company rights to commercialize its allergy treatment neffy in the country
Alfresa expects neffy to be available in Q4 2025 - SPRY
Up to last close, SPRY down 5.88% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey






